Close

BioLineRx (BLRX) Receives FDA Biological Product Designation for Novel Cancer Immunotherapy Candidate AGI-134

November 20, 2018 7:05 AM EST Send to a Friend
BioLineRx Ltd. (NASDAQ: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that the U.S. Food and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login